FDA Cracks Down on Mass‑Compounded GLP‑1 Drugs, Targeting Eli Lilly Supply Chains

Washington — FDA Commissioner Marty Makary says the agency is stepping up enforcement against unlawful mass compounding of GLP‑1 weight‑loss drugs, a move that has direct implications for branded manufacturers such as Eli Lilly. Speaking during a Washington visit and in an interview with CNBC’s Healthy Returns, Makary stresses the agency is addressing safety, quality and potential legal violations tied to pharmacies and telehealth firms that produce unapproved compounded versions of popular GLP‑1 medicines.

Crackdown zeroes in on supply and safety chains tied to Eli Lilly

Makary says the FDA is “serious” about targeting large‑scale compounding operations and is already taking action against telehealth company Hims & Hers for marketing compounded versions of Novo Nordisk’s Wegovy as pills and injections. He adds the agency plans to restrict GLP‑1 active pharmaceutical ingredients used in non‑approved compounded drugs, citing concerns over manufacturing quality, product consistency and federal law. The commissioner specifically notes inspectors are seeing more active ingredients sourced from Novo Nordisk and Eli Lilly, and he warns that companies and compounding pharmacies must “play by the rules” that govern clinical trials, labeling and safety disclosures.

Makary says restricting the ingredients and tightening enforcement will protect patients and preserve the regulated market that branded manufacturers follow, while potentially increasing compliant competition. He outlines enforcement tools that include direct talks with companies, regulatory sanctions, public letters to doctors and pharmacists, and, where necessary, legal action. The FDA hopes to curb illegal mass compounding by 2026 and frames the push as necessary to ensure that products meet the same standards as those produced and marketed by companies like Eli Lilly.

Context: vaccines and agency changes

Makary’s comments come amid broader turbulence at the FDA, including leadership transition, staff and budgetary pressures and shifts in vaccine and drug‑approval approaches. He says the agency’s guidance to manufacturers has been “pretty clear” in recent months.

Other regulatory moves

Separately, Makary is photographed holding a Lancet study as the Department of Health and Human Services announces plans to phase out petroleum‑based synthetic food dyes, underscoring a wider regulatory agenda even as the agency negotiates recent debates over Moderna’s experimental mRNA flu shot and its application process.